Y. Inoue

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Y Inoue, Y. Inoue, Yoshimasa Inoue
Publication record
96 papers · 1,524 citations · H-index 24

PAPERS

The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder
20217 citationsauthor #9
CYP2D6*10 polymorphism and the enantioselective O‐desmethylation of S‐(+)‐ and R‐(‐)‐venlafaxine in Japanese psychiatric patients
20215 citationsauthor #7
Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression
20204 citationsauthor #7
Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD
20205 citationsauthor #7
Pharmacokinetic analysis of enantiomers in Venlafaxine and O-desmethylvenlafaxine
20200 citationsauthor #3
Impact of CYP2D6*10 on venlafaxine and its desmethylated metabolite pharmacokinetics in Japanese psychiatric patients
20200 citationsauthor #3
Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia
20206 citationsauthor #7
P.331 Impact of CYP2D6*10 on pharmacokinetics of venlafaxine and its demethylated metabolite in Japanese psychiatric patients
20190 citationsauthor #3
8-Hydroxylation and Glucuronidation of Mirtazapine in Japanese Psychiatric Patients: Significance of the Glucuronidation Pathway of 8-Hydroxy-Mirtazapine
20181 citationsauthor #9
Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression
201816 citationsauthor #6
Sex Differences in the Effect of Atomoxetine on the QT Interval in Adult Patients With Attention-Deficit Hyperactivity Disorder
20176 citationsauthor #8
PS91. The effects of fluvoxamine on the steady-state plasma concentrations of escitalopram and desmethylescitalopram in depressed Japanese patients.
20160 citationsauthor #2
The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients
20167 citationsauthor #6
An attempt to construct a 7-item short version of the Temperament and Character Inventory to predict the treatment response of patients with depression
20160 citationsauthor #1
PS213. Pharmacokinetics of mirtazapine and its hydroxylated metabolite in Japanese psychiatric patients treated with mirtazapine
20160 citationsauthor #5
PS105. Effects of CYP2C19 genotype on steady-state plasma concentrations of escitalopram and desmetyl metabolite in Japanese depressed patients
20160 citationsauthor #2
Impact of CYP2D6*10 polymorphism on the pharmacokinetics of mirtazapine and its desmethylated metabolite in Japanese psychiatric patients treated with mirtazapine
20152 citationsauthor #8
Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients
20157 citationsauthor #8
Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
20140 citationsauthor #8
Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia
201425 citationsauthor #8
Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
20148 citationsauthor #8
Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
20140 citationsauthor #8
P.2.f.019 Effect of CYP2D6*10 polymorphism on mirtazapine metabolism in Japanese psychiatric patients
20140 citationsauthor #5
Interaction Between Paliperidone and Carbamazepine
201325 citationsauthor #5
Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients
201220 citationsauthor #8
QT prolongation of the antipsychotic risperidone is predominantly related to its 9‐hydroxy metabolite paliperidone
201238 citationsauthor #8
CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype–phenotype association study design in translational pharmacogenetics
201126 citationsauthor #6
Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder
201118 citationsauthor #8
Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder
201124 citationsauthor #9
P.4.a.007 FGF2 nor BDNF affect the therapeutic response of paroxetine in panic disorder measured by serotonergic gene polymorphisms and plasma levels of paroxetine
20110 citationsauthor #9
Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders
201125 citationsauthor #4
The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients.
20105 citationsauthor #8
A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies.
201037 citationsauthor #4
Effect of dose timing in relation to food intake on systemic exposure to blonanserin
201024 citationsauthor #3
Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients.
201015 citationsauthor #7
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients
20109 citationsauthor #6
P.4.e.008 The factors that influence the therapeutic response to paroxetine in patients with panic disorder: longitudinal study
20090 citationsauthor #6
Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder
200913 citationsauthor #6
Dose-Dependent Effect of the CYP2D6 Genotype on the Steady-state Fluvoxamine Concentration
200811 citationsauthor #6
Concentration-Response Relationship for Fluvoxamine Using Remission as an Endpoint: A Receiver Operating Characteristics Curve Analysis in Major Depression
200818 citationsauthor #7
Effect of Itraconazole on Pharmacokinetics of Paroxetine: The Role of Gut Transporters
200732 citationsauthor #4
Dose-Dependent Effects of the 3435 C>T Genotype of ABCB1 Gene on the Steady-State Plasma Concentration of Fluvoxamine in Psychiatric Patients
200741 citationsauthor #6
Rihga Royal Hotel Kokura, Kitakyushu, Japan Meeting theme: The Quest for More Precise Drug Therapy: Integrating Evidence and Narrative
20070 citationsauthor #9
Effects of Caffeine on the Kinetics of Fluvoxamine and its Major Metabolite in Plasma After a Single Oral Dose of the Drug
20065 citationsauthor #5
The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine
200673 citationsauthor #5
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects
200634 citationsauthor #3
Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity
200531 citationsauthor #4
Interaction Study Between Enoxacin and Fluvoxamine
200510 citationsauthor #7
Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography.
200518 citationsauthor #2
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.
200517 citationsauthor #6
Induction of the metabolism of etizolam by carbamazepine in humans
200515 citationsauthor #6
Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography.
200428 citationsauthor #2
Steady-State Pharmacokinetics of a New Antipsychotic Agent Perospirone and Its Active Metabolite, and Its Relationship with Prolactin Response
200418 citationsauthor #5
Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia
200420 citationsauthor #4
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
200485 citationsauthor #5
Establishment of new cloned enzyme donor immunoassays (CEDIA??) for haloperidol and bromperidol
20041 citationsauthor #4
Establishment of New Cloned Enzyme Donor Immunoassays (CEDIA®) for Haloperidol and Bromperidol
20042 citationsauthor #4
Sensitive determination of midazolam and 1'-hydroxymidazolam in plasma by liquid-liquid extraction and column-switching liquid chromatography with ultraviolet absorbance detection and its application for measuring CYP3A activity.
200423 citationsauthor #2
Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism
200431 citationsauthor #6
Significant Dose Effect of Carbamazepine on Reduction of Steady-State Plasma Concentration of Haloperidol in Schizophrenic Patients
200321 citationsauthor #5
Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography.
200324 citationsauthor #2
Poor Reliability of Therapeutic Drug Monitoring Data for Haloperidol and Bromperidol Using Enzyme Immunoassay
20034 citationsauthor #4
Histamine H1-Receptor Antagonists, Promethazine and Homochlorcyclizine, Increase the Steady-State Plasma Concentrations of Haloperidol and Reduced Haloperidol
200317 citationsauthor #6
Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles
200312 citationsauthor #7
Lack of Correlation between the Steady‐State Plasma Concentrations of Haloperidol and Risperidone
20029 citationsauthor #5
Evaluation of dextromethorphan N-demethylation activity as a biomarker for cytochrome P450 3A activity in man.
200210 citationsauthor #3
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
200169 citationsauthor #8
Effects of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of halperidol and reduced haloperidol in Japanese patients with schizophrenia
20010 citationsauthor #9
Evaluation of cytochrome P450 3A activity in vivo: Do dextromethorphan N-demethylation activity and urinary 6??-hydroxycortisol/cortisol ratio predict oral midazolam clearance?
20010 citationsauthor #3
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.
200148 citationsauthor #8
The various factors influencing therapeutic and side effects of bromperidol in schizophrenic patients
20010 citationsauthor #7
Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.
200114 citationsauthor #6
Importance of the Cytochrome P450 2D6 Genotype for the Drug Metabolic Interaction Between Chlorpromazine and Haloperidol
200119 citationsauthor #7
Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report
200125 citationsauthor #8
Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
20005 citationsauthor #5
Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
200016 citationsauthor #10
Oral presentation: Relationship between the change of plasma haloperidol concentrations caused by coadministration of carbamazepine and CYP2D6 genotype
19990 citationsauthor #7
Oral presentation: Relationship between plasma concentration of haloperidol and cytochrome P4502D6 genotypes
19990 citationsauthor #7
Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
199971 citationsauthor #9
Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
199920 citationsauthor #8
Oral presentation: Effect of coadministraion of chlorpromazine on the plasma concentration of haloperidol
19990 citationsauthor #11
Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
199932 citationsauthor #8
The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population
199935 citationsauthor #7
No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
19993 citationsauthor #10
Oral presentation: The effect of smoking on plasma haloperidol concentrations
19990 citationsauthor #9
Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients
199916 citationsauthor #8
Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
19983 citationsauthor #7
Prolactin response to bromperidol treatment in schizophrenic patients.
199825 citationsauthor #8
Cyp2d6 genotype and steady-state plasma concentrations (css) of haloperidol
19983 citationsauthor #7
Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite
199811 citationsauthor #9
No relationship between steady-state concentrations of haloperidol and bromperidol
19980 citationsauthor #7
Interaction between carbamazepine and bromperidol
199718 citationsauthor #9
Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.
199774 citationsauthor #6
No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
19979 citationsauthor #8
Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
199718 citationsauthor #8
No interaction between desipramine and bromperidol.
19963 citationsauthor #8

TIMELINE

1996 3 citations

1997 119 citations

1998 42 citations

1999 177 citations

2000 21 citations

2001 175 citations

2002 19 citations

2003 78 citations

2004 208 citations

2005 91 citations

2006 112 citations

2007 73 citations

2008 29 citations

2009 13 citations

2010 90 citations

2011 93 citations

2012 58 citations

2013 25 citations

2014 33 citations

2015 9 citations

2016 7 citations

2017 6 citations

2018 17 citations

2019 0 citations

2020 15 citations

2021 12 citations

Y. Inoue

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT